Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Research output: Contribution to journalArticle

Authors

Institutes & Expert groups

  • KUL - Katholieke Universiteit Leuven

Documents & links

Abstract

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

Details

Original languageEnglish
Article number599
Pages (from-to)1-25
Number of pages25
JournalPharmaceutics
Volume13
Issue number599
DOIs
Publication statusPublished - 21 Apr 2021

Keywords

  • Bismuth-213, Targeted Radionuclide Therapy, Targeted alpha therapy, Radiopharmaceutical, Bifunctional chelator, Vector molecule

ID: 7102090